Athersys Company Profile
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.
As represented by its name, (Athersys - derived from advanced therapeutic systems), the Company is committed to developing novel therapeutic products that deliver substantial improvements over existing therapies through the application and utilization of its advanced, proprietary technology platforms.
Through internal development and acquisition of key technologies, Athersys has established a unique blend of competencies in areas such as molecular biology, cell biology, genomics, protein biochemistry, medicinal chemistry, and pharmacology. The Company has fully integrated pre-clinical drug discovery and development capabilities, and is focused on advancing a portfolio of therapeutic development programs into the clinic.
3201 Carnegie Avenue
United States of America
Email: email@example.com., firstname.lastname@example.org
Partnerschaft im Bereich der regenerativen Medizin mit dem Schwerpunkt auf der Entwicklung einer neuen Stammzellentherapie CLEVELAND und TOKIO, 3. März 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nas...
Edison Investment Research - Pharmaceutical & Healthcare - Athersys : The development of regenerative medicines in Japan presents a significant opportunity. Athersys has just taken a major step toward...
Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic s...
Biospectrum As part of the collaboration, Chugai will be responsible for the development and commercialization of Multi...
Edison Investment Research - Pharmaceutical & Healthcare - Athersys : Enrolment in the potentially pivotal Phase II study assessing MultiStem in ischaemic stroke patients is now complete. With a 90-da...
Athersys agreed to collaborate with Chugai Pharmaceutical to develop and market in Japan the former's MultiStem cell therapy, -More-
Athersys and Chugai Pharmaceutical have announced a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic stroke repr...
The U.S. venture Athersys has entered into a cell therapy alliance with Chugai that will enable it to take advantage of the newly supportive regulatory environment in Japan for regenerative medicines ...
Drugs and Medications
Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.As represented by its name, (Ather...
Athersys is a biotechnology company engaged in the research and development of products for the treatment and diagnosis of genetic and immunologic disorders. The company has a core expertise in the f...
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company ...
More Information about "Athersys" on BioPortfolio
We have published hundreds of Athersys news stories on BioPortfolio along with dozens of Athersys Clinical Trials and PubMed Articles about Athersys for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Athersys Companies in our database. You can also find out about relevant Athersys Drugs and Medications on this site too.